Angiotensin receptors in GtoPdb v.2025.3

Authors

  • Wayne Alexander Emory University
  • Sadashiva Karnik Cleveland Clinic Lerner Research Institute https://orcid.org/0000-0003-0746-2753
  • Jacqueline Kemp Cleveland Clinic Lerner Research Institute
  • Luxmichan Laishram Cleveland Clinic Lerner Research Institute
  • Walter G. Thomas University of Queensland
  • Pieter B. M. W. M. Timmermans Tularik
  • Kalyan Tirupula Cleveland Clinic Lerner Research Institute
  • Hamiyet Unal Cleveland Clinic Lerner Research Institute
  • Thomas Unger Christian-Albrechts-Universität zu Kiel
  • Tadashi Inagami Vanderbilt University
  • Ahsan Husain University of Alabama at Birmingham
  • László Hunyady Semmelweis University
  • Kenneth E. Bernstein Cedars-Sinai Medical Center
  • Kevin J. Catt National Institutes of Health
  • Marc de Gasparo Novartis Institutes for Biomedical Research
  • Khuraijam Dhanachandra Singh Cleveland Clinic Lerner Research Institute https://orcid.org/0000-0003-0506-6896
  • Satoru Eguchi Temple University
  • Emanuel Escher Universite de Sherbrooke https://orcid.org/0000-0001-6601-987X
  • Theodore L. Goodfriend Veterans Administration Hospital Wisconsin
  • Mastgugu Horiuchi Ehime University
  • Patrick Vanderheyden Vrije Universiteit Brussel

DOI:

https://doi.org/10.2218/gtopdb/F6/2025.3

Abstract

The actions of angiotensin II (Ang II) are mediated by AT1 and AT2 receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Angiotensin receptors [63, 155]), which have around 30% sequence similarity. The octapeptide angiotensin II and the heptapeptide angiotensin III are endogenous ligands. The "sartan" family drugs such as losartan, candesartan, olmesartan, telmisartan, etc. are clinically used AT1 receptor blockers.

Downloads

Download data is not yet available.

Published

10-Sep-2025

Issue

Section

Articles

How to Cite

“Angiotensin receptors in GtoPdb v.2025.3” (2025) IUPHAR/BPS Guide to Pharmacology CITE, 2025(3). doi:10.2218/gtopdb/F6/2025.3.